Veristat rolled out InStat, a fully automated biostatistics platform built to compress clinical trial readout timelines from weeks to days. The system is designed to generate submission-ready tables, listings, and figures (TLF) in five days or less. Veristat said InStat uses validated statistical engines and biostatistician review, translating biostatistics descriptions into executable specifications. A secure collaboration portal is intended to let sponsors finalize readouts faster and reduce manual turnaround bottlenecks. Clene Nanomedicine is cited as the first customer, using InStat for neurofilament light (NfL) biomarker analyses associated with an accelerated approval pathway under Subpart H. For biotech teams, shorter and more predictable readout cycles can directly affect regulatory timing and commercialization revenue windows, especially for sponsors dependent on biomarker-driven decisions.